• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Nanotheranostics ˗ Application and Further Development of Nanomedicine Strategies for Advanced Theranostics
Nanotheranostics is to apply and further develop nanomedicine strategies for advanced theranostics. This review summarizes the various nanocarriers developed so far in the literature for nanotheranostics, which include polymer conjugations, dendrimers, micelles, liposomes, metal and inorganic nanoparticles, carbon nanotubes, and nanoparticles of biodegradable polymers for sustained, controlled and targeted co-delivery of diagnostic and therapeutic agents for better theranostic effects with fewer side effects. The theranostic nanomedicine can achieve systemic circulation, evade host defenses and deliver the drug and diagnos...
Source: Theranostics - November 15, 2014 Category: Molecular Biology Authors: Madaswamy S. Muthu, David Tai Leong, Lin Mei, Si-Shen Feng Tags: Review Source Type: research

Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
RNA interference (RNAi) is an endogenous post-transcriptional gene regulatory mechanism, where non-coding, double-stranded RNA molecules interfere with the expression of certain genes in order to silence it. Since its discovery, this phenomenon has evolved as powerful technology to diagnose and treat diseases at cellular and molecular levels. With a lot of attention, short interfering RNA (siRNA) therapeutics has brought a great hope for treatment of various undruggable diseases, including genetic diseases, cancer, and resistant viral infections. However, the challenge of their systemic delivery and on how they are integra...
Source: Theranostics - November 15, 2014 Category: Molecular Biology Authors: Mohamed Shehata Draz, Binbin Amanda Fang, Pengfei Zhang, Zhi Hu, Shenda Gu, Kevin C. Weng, Joe W. Gray, Fanqing Frank Chen Tags: Review Source Type: research

Megalin-Mediated Specific Uptake of Chitosan/siRNA Nanoparticles in Mouse Kidney Proximal Tubule Epithelial Cells Enables AQP1 Gene Silencing
In conclusion, specific targeting PTECs with the chitosan nanoparticle system may prove to be a useful strategy for knockdown of specific genes in PTECs, and provides a potential therapeutic strategy for treating various kidney diseases.
Source: Theranostics - November 15, 2014 Category: Molecular Biology Authors: Shan Gao, San Hein, Frederik Dagnæs-Hansen, Kathrin Weyer, Chuanxu Yang, Rikke Nielsen, Erik I Christensen, Robert A Fenton, Jørgen Kjems Tags: Research Paper Source Type: research

Co-delivery of Doxorubicin and Bmi1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo
Bmi1 gene overexpression is found in various human tumors and has been shown as a potential target for gene treatment. However, siRNA-based treatments targeting Bmi1 gene have been restricted to limited delivery, low bioavailability and hence relatively reduced efficacy. To overcome these barriers, we developed a folate receptor targeted co-delivery system folate-doxorubicin/Bmi1 siRNA liposome (FA-DOX/siRNA-L). The FA-DOX/siRNA-L was prepared through electrostatic interaction between folate doxorubicin liposome (FA-DOX-L) and Bmi1 siRNA. In vitro and in vivo studies showed that FA-DOX/siRNA-L inhibited tumor growth by com...
Source: Theranostics - November 15, 2014 Category: Molecular Biology Authors: Tan Yang, Bin Li, Shibo Qi, Yong Liu, Yongkang Gai, Peng Ye, Guang Yang, Wendian Zhang, Peng Zhang, Xingxing He, Weijie Li, Zhiping Zhang, Guangya Xiang, Chuanrui Xu Tags: Research Paper Source Type: research

Functional Nanostructures for Effective Delivery of Small Interfering RNA Therapeutics
Small interfering RNA (siRNA) has proved to be a powerful tool for target-specific gene silencing via RNA interference (RNAi). Its ability to control targeted gene expression gives new hope to gene therapy as a treatment for cancers and genetic diseases. However, siRNA shows poor pharmacological properties, such as low serum stability, off-targeting, and innate immune responses, which present a significant challenge for clinical applications. In addition, siRNA cannot cross the cell membrane for RNAi activity because of its anionic property and stiff structure. Therefore, the development of a safe, stable, and efficient sy...
Source: Theranostics - November 15, 2014 Category: Molecular Biology Authors: Cheol Am Hong, Yoon Sung Nam Tags: Review Source Type: research

Pages: 1  2  3  4  5  6  7  8